- Home
- LVLU vs LSTA Comparison
LVLU vs LSTA Comparison
Compare LVLU & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | LSTA |
|---|---|---|
| Founded | 1996 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 28.9M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | LVLU | LSTA |
|---|---|---|
| Price | $10.65 | $1.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 64.3K | ★ 683.9K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,284,000.00 | $35,283,868.00 |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $4.26 | $0.99 |
| 52 Week High | $32.32 | $5.07 |
Technical Indicators
Market Signals| Indicator | LVLU | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 50.29 |
| Support Level | $8.56 | $1.11 |
| Resistance Level | $11.21 | $2.08 |
| Average True Range (ATR) | 1.26 | 0.28 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 28.63 | 31.37 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates the majority of its revenue from customers based in the United States.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.